FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004368416> ?p ?o ?g. }

• W2004368416 endingPage "1650" @default.
• W2004368416 startingPage "1644" @default.
• W2004368416 abstract "Study Objectives. To assess the effectiveness and tolerability of caspofungin as primary prophylaxis against invasive fungal infections in stem cell transplant recipients who are poor candidates for triazole or lipid amphotericin B prophylaxis due to renal or hepatic dysfunction, and to determine whether any patient characteristics are independently associated with an increased risk of breakthrough invasive fungal infection during caspofungin prophylaxis. Design. Retrospective medical record review. Setting. Tertiary care comprehensive cancer center. Patients. One hundred twenty-three adult stem cell transplant recipients who received caspofungin 35–50 mg/day for up to 100 days after transplantation as primary antifungal prophylaxis between January 1, 2002, and June 30, 2005. Measurements and Main Results. Data were collected on host and transplant characteristics such as transplant type, neutropenia, graft-versus-host disease (GVHD), and corticosteroid use, as well as evidence of break-through invasive fungal infections. Of the 123 patients, 117 (95.1%) were allogeneic recipients, and the median time to engraftment was 12 days (range 6–26 days). Fifty (40.7%) of the patients developed GVHD of grade 2 or greater and received corticosteroids for more than 21 days. Median duration of caspofungin prophylaxis was 73 days (range 10–100 days). Nine patients (7.3%) developed breakthrough invasive fungal infections (two cases of mixed Aspergillus species and one each of Aspergillus terreus, Rhizopus, Exserohilum, an unspecified mold, Cryptococcus, Candida glabrata, and Candida tropicalis). Median time to invasive fungal infection development was 65 days (range 12–88 days). Only one case occurred during the neutropenic period before engraftment. Multivariate analysis showed that Pseudomonas coinfection (p=0.04) and infliximab therapy (p=0.02) were associated with breakthrough invasive fungal infections in patients receiving caspofungin. By day 100, there were five (4.1%) deaths, two of which were directly attributable to invasive fungal infections. No caspofungin-related adverse events were reported. Conclusion. Caspofungin seems to be an effective and well-tolerated option for primary antifungal prophylaxis in the highly immunosuppressed stem cell transplant patient population." @default.
• W2004368416 created "2016-06-24" @default.
• W2004368416 creator A5003703624 @default.
• W2004368416 creator A5005544421 @default.
• W2004368416 creator A5041039527 @default.
• W2004368416 creator A5048913229 @default.
• W2004368416 creator A5066067579 @default.
• W2004368416 date "2007-12-01" @default.
• W2004368416 modified "2023-09-26" @default.
• W2004368416 title "Caspofungin as Primary Antifungal Prophylaxis in Stem Cell Transplant Recipients" @default.
• W2004368416 cites W1969880613 @default.
• W2004368416 cites W1988385266 @default.
• W2004368416 cites W2012951272 @default.
• W2004368416 cites W2066381032 @default.
• W2004368416 cites W2082007625 @default.
• W2004368416 cites W2096480959 @default.
• W2004368416 cites W2099951777 @default.
• W2004368416 cites W2114416009 @default.
• W2004368416 cites W2118209160 @default.
• W2004368416 cites W2133328722 @default.
• W2004368416 cites W2147556278 @default.
• W2004368416 cites W2152847141 @default.
• W2004368416 cites W2167412063 @default.
• W2004368416 cites W2341266869 @default.
• W2004368416 doi "https://doi.org/10.1592/phco.27.12.1644" @default.
• W2004368416 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18041885" @default.
• W2004368416 hasPublicationYear "2007" @default.
• W2004368416 type Work @default.
• W2004368416 sameAs 2004368416 @default.
• W2004368416 citedByCount "65" @default.
• W2004368416 countsByYear W20043684162012 @default.
• W2004368416 countsByYear W20043684162013 @default.
• W2004368416 countsByYear W20043684162014 @default.
• W2004368416 countsByYear W20043684162015 @default.
• W2004368416 countsByYear W20043684162016 @default.
• W2004368416 countsByYear W20043684162017 @default.
• W2004368416 countsByYear W20043684162018 @default.
• W2004368416 countsByYear W20043684162019 @default.
• W2004368416 countsByYear W20043684162020 @default.
• W2004368416 countsByYear W20043684162021 @default.
• W2004368416 crossrefType "journal-article" @default.
• W2004368416 hasAuthorship W2004368416A5003703624 @default.
• W2004368416 hasAuthorship W2004368416A5005544421 @default.
• W2004368416 hasAuthorship W2004368416A5041039527 @default.
• W2004368416 hasAuthorship W2004368416A5048913229 @default.
• W2004368416 hasAuthorship W2004368416A5066067579 @default.
• W2004368416 hasConcept C126322002 @default.
• W2004368416 hasConcept C141071460 @default.
• W2004368416 hasConcept C16005928 @default.
• W2004368416 hasConcept C2776694085 @default.
• W2004368416 hasConcept C2777063308 @default.
• W2004368416 hasConcept C2777408962 @default.
• W2004368416 hasConcept C2779548794 @default.
• W2004368416 hasConcept C2779629538 @default.
• W2004368416 hasConcept C2780252810 @default.
• W2004368416 hasConcept C2780402444 @default.
• W2004368416 hasConcept C2780690907 @default.
• W2004368416 hasConcept C2911091166 @default.
• W2004368416 hasConcept C71924100 @default.
• W2004368416 hasConcept C90924648 @default.
• W2004368416 hasConceptScore W2004368416C126322002 @default.
• W2004368416 hasConceptScore W2004368416C141071460 @default.
• W2004368416 hasConceptScore W2004368416C16005928 @default.
• W2004368416 hasConceptScore W2004368416C2776694085 @default.
• W2004368416 hasConceptScore W2004368416C2777063308 @default.
• W2004368416 hasConceptScore W2004368416C2777408962 @default.
• W2004368416 hasConceptScore W2004368416C2779548794 @default.
• W2004368416 hasConceptScore W2004368416C2779629538 @default.
• W2004368416 hasConceptScore W2004368416C2780252810 @default.
• W2004368416 hasConceptScore W2004368416C2780402444 @default.
• W2004368416 hasConceptScore W2004368416C2780690907 @default.
• W2004368416 hasConceptScore W2004368416C2911091166 @default.
• W2004368416 hasConceptScore W2004368416C71924100 @default.
• W2004368416 hasConceptScore W2004368416C90924648 @default.
• W2004368416 hasIssue "12" @default.
• W2004368416 hasLocation W20043684161 @default.
• W2004368416 hasLocation W20043684162 @default.
• W2004368416 hasOpenAccess W2004368416 @default.
• W2004368416 hasPrimaryLocation W20043684161 @default.
• W2004368416 hasRelatedWork W1977758433 @default.
• W2004368416 hasRelatedWork W2000625508 @default.
• W2004368416 hasRelatedWork W2051671935 @default.
• W2004368416 hasRelatedWork W2126888301 @default.
• W2004368416 hasRelatedWork W2146546900 @default.
• W2004368416 hasRelatedWork W2147911436 @default.
• W2004368416 hasRelatedWork W2793993273 @default.
• W2004368416 hasRelatedWork W2921750695 @default.
• W2004368416 hasRelatedWork W4299363870 @default.
• W2004368416 hasRelatedWork W4385673125 @default.
• W2004368416 hasVolume "27" @default.
• W2004368416 isParatext "false" @default.
• W2004368416 isRetracted "false" @default.
• W2004368416 magId "2004368416" @default.
• W2004368416 workType "article" @default.